Pharmacogenetics Testing Leads Molecular Diagnostic Growth Potential
Molecular tests in the area of pharmacogenetics will lead the explosive growth of the molecular diagnostic segment over the next 10 years, according to a new study released today from Kalorama Information. Pharmacogenetics involves testing an individualÂ’s genetic make-up to determine which drug regimen will best benefit his or her condition.
New York (PRWEB) May 14, 2004 -
— Molecular tests in the area of pharmacogenetics will lead the explosive growth of the molecular diagnostic segment over the next 10 years, according to a new study released today from Kalorama Information. Pharmacogenetics involves testing an individual’s genetic make-up to determine which drug regimen will best benefit his or her condition.
The new study, "The U. S. Market for Molecular Diagnostics, 2nd Ed.," found that pharmacogenetics, representing just 2% of molecular testing at this time, will display average annual growth of near 200% through 2013 and eventually represent the largest segment in terms of dollar volume. Molecular testing in cancer (both susceptibility and monitoring) also has near 200% growth potential, but has a smaller overall market than pharmacogenetics.
"Pharmacogenetics is currently all about HIV/AIDS therapeutics," notes Kenneth G. Krul, Ph. D., the author of the report. "But new discoveries in other areas will vastly increase the opportunity for this type of testing. New discoveries in the field of mental health, in particular, and the relationship of the genetic signatures of neuropsychiatric disorders to optimal treatment procedures will represent a significant growth area for pharmacogenetics."
The 628-page study comprehensively reviews the technologies, applications, players, and markets for molecular diagnostics. Applications include pharmacogenetics, blood banking, cancer, infectious disease testing, and genetic/chromosomal disease testing. Market potential, testing volume, and average test cost is estimated through 2013 for dozens of analytes across these testing areas. The report also includes issues and challenges facing marketers, strategic implications of the studyÂ’s conclusions, and extensive profiles of 30 industry leaders.
This new report is priced at $3500 and is available for purchase at http://www. kaloramainformation. com/pub/943017.htmlor (http://www. kaloramainformation. com/pub/943017.htmlor) at www. MarketResearch. com.
About Kalorama Information
Kalorama Information, a life sciences publishing division of MarketResearch. com, supplies the latest in independent market research for the life sciences. For more information, contact Steven Heffner, editor for Kalorama Information, at 212-807-2634 or sheffner@kaloramainformation. com, or visit www. KaloramaInformation. com.
###